SNN Introduces ALLEVYN COMPLETE CARE Dressing for Advanced Wound Treatment

Smith + Nephew Unveils ALLEVYN COMPLETE CARE Foam Dressing

Smith + Nephew (SNN) has introduced ALLEVYN COMPLETE CARE Foam Dressing, a new advanced product aimed at improving wound care and preventing pressure injuries.

Impact on SNN’s Advanced Wound Management Portfolio

This launch bolsters Smith + Nephew’s Advanced Wound Management segment, a strategic area for the company’s expansion. As chronic wounds and pressure injuries continue to challenge healthcare systems worldwide, innovative offerings like ALLEVYN COMPLETE CARE may encourage greater clinical use, enhance SNN’s market position, and drive sustained revenue growth in the wound care sector.

Stock Performance After the Announcement

Following the product launch, SNN’s stock dropped by 2.9% in the latest trading session. Over the past six months, the company’s shares have declined by 14.2%, while the broader industry fell 18%. In contrast, the S&P 500 index rose 4.1% during the same period.

Looking ahead, ALLEVYN COMPLETE CARE is expected to reinforce SNN’s standing in the advanced wound care market, which is experiencing increased demand due to the rising incidence of chronic wounds and pressure injuries. The product’s improved absorption, infection defense, and extended wear time could make it a preferred choice for hospitals and clinicians, supporting SNN’s growth and recurring sales in this field.

Smith + Nephew currently has a market capitalization of $14.48 billion.

Image Source: Zacks Investment Research

Details About ALLEVYN COMPLETE CARE

The ALLEVYN COMPLETE CARE Foam Dressing is engineered as a next-generation solution for wound care and pressure injury prevention. It features a unique five-layer design with proprietary technology to manage wound exudate and protect delicate skin.

According to Smith + Nephew, this dressing can retain significantly more exudate than standard foam dressings and blocks over 99% of bacteria from reaching the wound. This reduces leakage, allows for longer wear, and minimizes dressing changes, supporting uninterrupted healing. The product was developed in collaboration with healthcare professionals and patients globally to address real-world clinical needs.

A standout aspect is its unbonded multilayer sliding structure, which disperses mechanical forces before they impact the skin and underlying tissues. This design can absorb up to 93% of mechanical energy, potentially lowering the risk of pressure injuries by more than 65%, based on supporting research. By combining superior exudate management with biomechanical protection, the dressing aims to improve patient comfort and clinical outcomes. ALLEVYN COMPLETE CARE will be available in various shapes and sizes to meet diverse wound care requirements.

The initial launch is in the United States, with plans to expand availability to Europe and other international markets in 2026, broadening its global reach.

Positive Outlook for the Wound Care Market

The global wound care market is projected to grow from $24.08 billion in 2025 to $33.62 billion by 2033, with a compound annual growth rate of 4.28% between 2026 and 2033.

This growth is driven by an increasing number of surgeries and a higher prevalence of chronic health conditions worldwide, fueling demand for advanced wound care products.

Recent Strategic Moves by Smith + Nephew

In January, Smith + Nephew expanded its Sports Medicine portfolio by acquiring Integrity Orthopaedics, a U.S.-based company specializing in the Tendon Seam rotator cuff repair system. This acquisition brings advanced repair technology aimed at reducing re-tear rates in the growing shoulder repair market and aligns with SNN’s focus on impactful innovation.

SNN’s Current Zacks Rank and Notable Peers

Smith + Nephew currently holds a Zacks Rank #3 (Hold).

Other medical sector stocks with higher Zacks rankings include:

• Intuitive Surgical (ISRG): Zacks Rank #1 (Strong Buy). The company reported Q4 2025 adjusted EPS of $2.53, surpassing estimates by 12.4%, with revenues of $2.87 billion exceeding expectations by 4.7%. Estimated long-term earnings growth is 15.7%, outpacing the industry’s 14%. The company has exceeded earnings estimates in the last four quarters, with an average surprise of 13.2%.
• Phibro Animal Health (PAHC): Zacks Rank #1. Fiscal Q2 2025 adjusted EPS was 87 cents, beating estimates by 26.1%, with revenues of $373.9 million, 4.7% above expectations. The company’s long-term earnings growth rate is projected at 21.5%, compared to the industry’s 12.6%, and it has beaten earnings estimates in the last four quarters with an average surprise of 20.1%.
• Cardinal Health (CAH): Zacks Rank #2 (Buy). The company posted Q2 fiscal 2026 adjusted EPS of $2.63, exceeding estimates by 10%, and revenues of $65.6 billion, 0.9% above expectations. Long-term earnings growth is estimated at 15%, compared to the industry’s 9.1%, with an average earnings surprise of 9.3% over the last four quarters.

Quantum Computing: The Next Big Opportunity

Quantum computing is emerging as a transformative technology, potentially surpassing even artificial intelligence in impact. Major tech companies like Microsoft, Google, Amazon, Oracle, Meta, and Tesla are rapidly integrating quantum computing into their operations.

Senior Stock Strategist Kevin Cook has identified seven stocks poised to lead in quantum computing, detailed in his report, Beyond AI: The Quantum Leap in Computing Power. Kevin, who recognized NVIDIA’s potential early on, now highlights quantum computing as the next major investment opportunity.

Additional Resources